85 results on '"Turkoz, Ibrahim"'
Search Results
2. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study
3. Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia
4. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
5. Longitudinal Clinical and MRI Outcomes in Relapsing Multiple Sclerosis (RMS) Patients After Short-term Ponesimod Treatment Interruption and Re-initiation (P6-3.007)
6. Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare system
7. Predictors of response and remission in patients with treatment-resistant depression: a post hoc pooled analysis of two acute trials of esketamine nasal spray
8. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability
9. Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
10. Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
11. Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective
12. Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study
13. Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study
14. Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections
15. Treatment Response to Esketamine Nasal Spray in Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Without Evidence of Early Response: A Pooled Post Hoc Analysis of ASPIRE
16. Effect of Ponesimod Compared With Teriflunomide on Treatment With Concomitant Corticosteroids for Relapse in Patients with Relapsing Forms of Multiple Sclerosis (P5-4.008)
17. Relationships Between Brain Volume and Disability, Cognition, Motor Function, and MS-Fatigue in Relapsing Multiple Sclerosis: MS-Fatigue and Ambulation Move at Their Own Pace (P1-1.Virtual)
18. The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder
19. Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
20. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
21. The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
22. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response
23. Clinically meaningful changes on depressive symptom measures and patient‐reported outcomes in patients with treatment‐resistant depression
24. Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
25. Suicide Ideation and Behavior Assessment Tool (SIBAT): Evaluation of Intra- and Inter-Rater Reliability, Validity, and Mapping to Columbia Classification Algorithm of Suicide Assessment
26. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
27. Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
28. A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics
29. S32. EFFICACY AND SAFETY OF PALIPERIDONE PALMITATE ONCE-MONTHLY IN PATIENTS WITH SCHIZOPHRENIA WITH LOW, MODERATE, AND HIGH RECENT DISEASE ACTIVITY AT BASELINE
30. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
31. Application of Bayesian analyses to doubly randomized delayed start, matched control designs to demonstrate disease modification
32. Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
33. Methodological challenges in indirect treatment comparisons
34. Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
35. Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses
36. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder
37. Bayesian blinded sample size re-estimation
38. Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety
39. Paliperidone Palmitate Improves and Maintains Functioning in Asia–Pacific Patients with Schizophrenia
40. Does Half-Life Matter After Antipsychotic Discontinuation?
41. Global sensitivity analysis for repeated measures studies with informative drop-out: A semi-parametric approach
42. 521. Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia
43. 522. The Difference in Clinical Outcome and Safety in Recent Diagnosis and Chronic Schizophrenic Disease after Paliperidone Palmitate 1 Month (PP1M) Treatment in Asian Patients
44. Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder
45. SA12. Baseline Demographics and Clinical Characteristics From a Prospective, Randomized, Open-Label Study of Paliperidone Palmitate Long-Acting Injection in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder
46. Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
47. Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder
48. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy
49. Paliperidone for the treatment of schizoaffective disorder
50. Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.